19 research outputs found
Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)
Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version "Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)". The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility
Cellular therapies for treating pain associated with spinal cord injury
Spinal cord injury leads to immense disability and loss of quality of life in human with no satisfactory clinical cure. Cell-based or cell-related therapies have emerged as promising therapeutic potentials both in regeneration of spinal cord and mitigation of neuropathic pain due to spinal cord injury. This article reviews the various options and their latest developments with an update on their therapeutic potentials and clinical trialing
In vitro Differentiation of Adult Adipose Mesenchymal Stem Cells into Retinal Progenitor Cells
Ozone therapy with local cellular immune modulation and disc progenitor cell implant is safe, effective and efficient
Low Back Pain (LBP) is a major cause of morbidity with significant economic impact through loss of work (15% in the United Kingdom). Additionally, there is the cost of health care and social support for the affected individual and their family. It is estimated that more than half the population (49%-70%) will experience significant LBP during their lives. Point prevalence from 12% to 30% is reported in western countries [1,2]. </p
Adoptive transfer of IL-10+ regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model
Treatment by Human Fetal Neuronal Tissue Transplant from Brain and Spinal Cord at Heterotopic Site in Axilla in Case of Posttraumatic Quadriplegia: A Report of Two Cases
Label-Free, Flow-Imaging Methods for Determination of Cell Concentration and Viability
Personalised Therapeutic
Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells
Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)
From Crossref journal articles via Jisc Publications RouterHistory: epub 2018-04-11Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version “Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)”. The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility